Top

Journal of Cachexia, Sarcopenia and Muscle

Published in:

Open Access 01-09-2010 | Review

Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training

Authors: Karsten Lenk, Gerhard Schuler, Volker Adams

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 1/2010

Abstract

Skeletal muscle is the most abundant tissue in the human body, and the maintenance of its mass is essential to ensure basic function as locomotion, strength and respiration. The decision to synthesize or to break down skeletal muscle proteins is regulated by a network of signaling pathways that transmit external stimuli to intracellular factors regulating gene transcription. The tightly regulated balance of muscle protein breakdown and synthesis is disturbed in several distinct myopathies, but also in two pathologies: sarcopenia and cachexia. In recent years, it became evident that in these two muscle wasting disorders specific regulating molecules are increased in expression (e.g. members of the ubiquitin–proteasome system, myostatin, apoptosis inducing factors), whereas other factors (e.g. insulin-like growth factor 1) are down-regulated. So far, not many treatment options to fight the muscle loss are available. One of the most promising approaches is exercise training that, due to its multifactorial effects, can act on several signaling pathways. Therefore, this review will concentrate on specific alterations discussed in the current literature that are present in the skeletal muscle of both muscle wasting disorders. In addition, we will focus on exercise training as an intervention strategy.

Carmeli E, Coleman R, Reznick AZ. The biochemistry of aging muscle. Exp Gerontol. 2002;37:477–89.PubMed

Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63.PubMed

Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol. 1977;43:1001–6.PubMed

Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970;19:653–63.PubMed

Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMed

Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.PubMed

Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol. 2005;6:439–48.PubMed

Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399–412.PubMed

Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007;6:458–71.PubMed

10.

Dodd SL, Gagnon BJ, Senf SM, Hain BA, Judge AR. Ros-mediated activation of NF-kappaB and Foxo during muscle disuse. Muscle Nerve. 2010;41:110–3.PubMed

11.

Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer. 2001;85:297–302.PubMed

12.

Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, et al. PGC-1α¦ protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 2006;103:16260–5.PubMed

13.

Glass DJ. Signaling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol. 2003;5:87–90.PubMed

14.

Guttridge DC. Signaling pathways weigh in on decisions to make or to break skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004;7:443–50.PubMed

15.

Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996;335:1897–905.PubMed

16.

Bardag-Gorce F, Farout L, Veyrat-Durebex C, Briand Y, Briand M. Changes in 20 S proteasome activity during ageing of the LOU rat. Mol Biol Rep. 1999;26:89–93.PubMed

17.

Clavel S, Coldefy AS, Kurkdjian E, Salles J, Margarites I, Derijard B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mech Ageing Dev. 2006;127:794–801.PubMed

18.

Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol A Biol Sci Med Sci. 2007;62:1407–12.PubMed

19.

DeRuisseau KC, AN KAVAZIS, Powers SK. Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Exp Gerontol. 2005;40:526–31.PubMed

20.

Edström E, Altun M, Hägglund M, Ulfhake B. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. J Gerontol A Biol Sci Med Sci. 2006;61:663–74.PubMed

21.

Du XL, Sui GZ, Stockklauser-Farber K, Weiss J, Zink S, Schwippert B, et al. Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia. 1998;41:249–56.PubMed

22.

Bossola M, Pacelli F, Costelli P, Tortorelli A, Rosa F, Doglietto G. Proteasome activities in the rectus abdominis muscle of young and older individuals. Biogerontology. 2008;9:261–8.PubMed

23.

Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83:731–801.PubMed

24.

Wendt A, Thompson VF, Goll DE. Interaction of calpastatin with calpain: a review. Biol Chem. 2004;385:465–72.PubMed

25.

Dargelos E, Brule C, Combaret L, Hadj-Sassi A, Dulong S, Poussard S, et al. Involvement of the calcium-dependent proteolytic system in skeletal muscle aging. Exp Gerontol. 2007;42:1088–98.PubMed

26.

Pattison JS, Folk LC, Madsen RW, Childs TE, Booth FW. Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle. Physiol Genomics. 2003;15:34–43.PubMed

27.

O’Connell K, Gannon J, Doran P, Ohlendieck K. Proteomic profiling reveals a severely perturbed protein expression pattern in aged skeletal muscle. Int J Mol Med. 2007;20:145–53.PubMed

28.

Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195–200.PubMed

29.

Dennis RA, Przybyla B, Gurley C, Kortebein PM, Simpson P, Sullivan DH, et al. Aging alters gene expression of growth and remodeling factors in human skeletal muscle both at rest and in response to acute resistance exercise. Physiol Genomics. 2008;32:393–400.PubMed

30.

Welle S, Bhatt K, Shah B, Thornton CA. Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62–77 and 21–31 year old men. Exp Gerontol. 2002;37:833–9.PubMed

31.

Williams A, Sun X, Fischer JE, Hasselgren PO. The expression of genes in the ubiquitin–proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 1999;126:744–9.PubMed

32.

Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos VE, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004;18:39–51.PubMed

33.

Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004;114:370–8.PubMed

34.

Liu CM, Yang Z, Liu CW, Wang R, Tien P, Dale R, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 2007;14:945–52.PubMed

35.

Jagoe RT, Redfern CP, Roberts RG, Gibson GJ, Goodship TH. Skeletal muscle mRNA for cathepsin B but not components of the ubiquitin–proteasome pathway are increased in patients with lung cancer referred for thoracotomy. Clin Sci. 2002;102:353–61.PubMed

36.

Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006;291:R674–83.PubMed

37.

Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left ventricular dysfunction. Circ Res. 2005;97:418–26.PubMed

38.

Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J. 2007;407:113–20.PubMed

39.

Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest. 1996;97:2509–016.PubMed

40.

Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 1996;15:1753–65.PubMed

41.

Li YP, Schwartz RJ, Wadell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NFkB activation in response to tumor necrosis factor a. FASEB J. 1998;12:871–80.PubMed

42.

Laviano A, Meguid MM, Preziosa I, Fanelli FR. Oxidative stress and wasting in cancer. Curr Opin Clin Nutr Metab Care. 2007;10:449–56.PubMed

43.

Li YP, Chen Y, Li AS, Reid MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol. 2003;285:C806–12.PubMed

44.

Gomes-Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 2002;180:69–74.PubMed

45.

Siu PM, Wang Y, Alway SE. Apoptotic signaling induced by H₂O₂-mediated oxidative stress in differentiated C2C12 myotubes. Life Sci. 2009;84:468–81.PubMed

46.

Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298–300.PubMed

47.

Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996;273:59–63.PubMed

48.

Feng J, Xie H, Meany DL, Thompson LV, Arriaga EA, Griffin TJ. Quantitative proteomic profiling of muscle type-dependent and age-dependent protein carbonylation in rat skeletal muscle mitochondria. J Gerontol A Biol Sci Med Sci. 2010;63:1137–52.

49.

Howard C, Ferrucci L, Sun K, Fried LP, Walston J, Varadhan R, et al. Oxidative protein damage is associated with poor grip strength among older women living in the community. J Appl Physiol. 2007;103:17–20.PubMed

50.

Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids. 2003;25:295–311.PubMed

51.

Barreiro E, Coronell C, Lavina B, Ramirez-Sarmiento A, Orozco-Levi M, Gea J. Aging, sex differences, and oxidative stress in human respiratory and limb muscles. Free Radic Biol Med. 2006;41:797–809.PubMed

52.

Fugere NA, Ferrington DA, Tompson LV. Protein nitration with aging in the rat semimembranosus and soleus muscles. J Gerontol A Biol Sci Med Sci. 2006;61:806–12.PubMed

53.

Thompson LV, Durand D, Fugere NA, Ferrington DA. Myosin and actin expression and oxidation in aging muscle. J Appl Physiol. 2006;101:1581–7.PubMed

54.

Kanski J, Hong SJ, Schoeneich C. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem. 2005;280:24261–6.PubMed

55.

Donoghue P, Staunton L, Mullen E, Manning G, Ohlendieck K. DIGE analysis of rat skeletal muscle proteins using nonionic detergent phase extraction of young adult versus aged gastrocnemius tissue. J Proteomics. 2010;73:1441–53.

56.

Barreiro E, de la Puente B, Busquets S, Lοpez-Soriano FJ, Gea J, Argiles JM. Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett. 2005;579:1646–52.PubMed

57.

Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso M, et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med. 2003;81:664–73.PubMed

58.

Levine B, Kalman J, Mayer L, Fillit HM, Packer MP. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–41.PubMed

59.

Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin Jr AS. NF-kappa B-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000;289:2363–6.PubMed

60.

Li YP, Reid MB. NF-kB mediates the protein loss induced by TNF-α in differentiated skeletal muscle. Am J Physiol. 2000;279:R1165–70.

61.

Adams V, Linke A, Wisloff U, Doring C, Erbs S, Krankel N, et al. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res. 2007;73:120–9.PubMed

62.

Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 2005;19:362–70.PubMed

63.

Adams V, Mangner N, Gasch A, Krohne C, Gielen S, Hirner S, et al. Induction of MuRF1 Is essential for TNF-[alpha]-induced loss of muscle function in mice. J Mol Biol. 2008;384:48–59.PubMed

64.

Tisdale MJ. BIOMEDICINE: protein loss in cancer cachexia. Science. 2000;289:2293–4.PubMed

65.

Schaap LA, Pluijm SMF, Deeg DJH, Harris TB, Kritchevsky SB, Newman AB, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64A:1183–9.

66.

Rieu I, Magne H, Savary-Auzeloux I, Averous J, Bos C, Peyron MA, et al. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J Physiol. 2009;587:5483–92.PubMed

67.

Balage M, Averous J, Remond D, Bos C, Pujos-Guillot E, Papet I, et al. Presence of low-grade inflammation impaired postprandial stimulation of muscle protein synthesis in old rats. J Nutr Biochem. 2010;21:325–31.PubMed

68.

Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev. 1999;19:223–48.PubMed

69.

Llovera M, Garcia-Martinez C, Lopez-Soriano J, Carbo N, Agell N, Lopez-Soriano FJ, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998;142:183–9.PubMed

70.

Adams V, Nehrhoff B, Späte U, Linke A, Schulze PC, Baur A, et al. Induction of iNOS-expression in skeletal muscle by IL-1β and NFκβ activation: an in vitro and in vivo study. Cardiovasc Res. 2002;54:95–104.PubMed

71.

Ungureanu-Longrois D, Balligand JL, Kelly RA, Smith TW. Myocardial contractility dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol. 1995;27:155–67.PubMed

72.

Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961;9:493–5.PubMed

73.

DEcary S, Mouly V, Hamida CB, Sautet A, Barbet JP, Butler-Browne GS. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum Gene Ther. 1997;8:1429–38.PubMed

74.

Olson EN, Klein WH. bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev. 1994;1:1–8.

75.

Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 1996;10:1173–83.PubMed

76.

Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem. 2005;280:2847–56.PubMed

77.

McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci. 2005;118:3531–41.PubMed

78.

McFarlane C, Hennebry A, Thomas M, Plummer E, Ling N, Sharma M, et al. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp Cell Res. 2008;314:317–29.PubMed

79.

Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell. 2000;102:777–86.PubMed

80.

Zaccagnini G, Martelli F, Magenta A, Cencioni C, Fasanaro P, Nicoletti C, et al. p66ShcA and oxidative stress modulate myogenic differentiation and skeletal muscle regeneration after hind limb ischemia. J Biol Chem. 2007;282:31453–9.PubMed

81.

Adams V, Gielen S, Hambrecht R, Schuler G. Apoptosis in skeletal muscle. Front Biosci. 2001;6:d1–d11.PubMed

82.

Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest. 2004;113:115–23.PubMed

83.

Argiles JM, Lopez-Soriano FJ, Busquets S. Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol. 2008;40:1674–8.PubMed

84.

Snow MH. The effects of aging on satellite cells in skeletal muscles of mice and rats. Cell Tissue Res. 1977;185:399–408.PubMed

85.

Gibson MC, Schultz E. Age-related differences in absolute numbers of skeletal muscle satellite cells. Muscle Nerve. 1983;6:574–80.PubMed

86.

Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. Muscle Nerve. 2004;20:120–7.

87.

Brooks NE, Schuenke MD, Hikida RS. No change in skeletal mucle satellite cells in young and aging rat soleus muscle. J Physiol Sci. 2009;59:465–71.PubMed

88.

Roth SM, Martel GF, Ivey FM, Lemmer JT, Metter EJ, Hurley BF, et al. Skeletal muscle satellite cell populations in healthy young and older men and women. Anat Rec. 2000;260:351–8.PubMed

89.

Leiter JRS, Anderson JE. Satellite cells are increasingly refractory to activation by nitric oxide and stretch in aged mouse-muscle cultures. Int J Biochem Cell Biol. 2010;42:132–6.PubMed

90.

Fulle S, Di Donna S, Puglielli C, Pietrangelo T, Beccafico S, Bellomo R, et al. Age-dependent imbalance of the antioxidative system in human satellite cells. Exp Gerontol. 2005;40:189–97.PubMed

91.

Haddad F, Adams GR. Aging-sensitive cellular and molecular mechnisms associated with skeletal muscle hypertroph. J Appl Physiol. 2006;100:1188–203.PubMed

92.

Kawada S, Tachi C, Ishii N. Content and localization of myostatin in mouse skeletal muscles during aging, mechanical unloading and reloading. J Muscle Res Cell Motil. 2001;22:627–33.PubMed

93.

Leger B, Derave W, DeBock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008;11:163–75.PubMed

94.

Baumann AP, Ibebunjo C, Grasser WA, Paralker VM. Myostatin expression in age and denervation-induced skeletal muscle atrophy. J Musculoskelet Neuronal Interact. 2003;3:8–16.PubMed

95.

Chabi B, Ljubicic V, Menzies KJ, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell. 2008;7:2–12.PubMed

96.

Rice KM, Blough ER. Sarcopenia-related apoptosis is regulated differently in fast- and slow-twitch muscles of the aging F344/N × BN rat model. Mech Ageing Dev. 2006;127:670–9.PubMed

97.

Wohlgemuth SE, Seo AY, Marzetti E, Lees HA, Leeuwenburgh C. Skeletal muscle autophagy and apoptosis during aging: effects of calorie restriction and life-long exercise. Exp Gerontol. 2010;45:138–48.PubMed

98.

Marzetti E, Wohlgemuth SE, Lees HA, Chung HY, Giovannini S, Leeuwenburgh C. Age-related activation of mitochondrial caspase-independent apoptotic signaling in rat gastrocnemius muscle. Mech Ageing Dev. 2008;129:542–9.PubMed

99.

Musaro A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci USA. 2004;101:1206–10.PubMed

100.

Benny Klimek ME, Aydogdu T, link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010;391:1548–54.PubMed

101.

Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, et al. Deacetylase inhibitors modulate myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets. 2009;9:608–19.PubMed

102.

van Royen M, Carbo N, Busquets S, Alvarez B, Quinn LS, Lopez-Soriano FJ, et al. DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun. 2000;270:533–7.PubMed

103.

Busquets S, Deans C, Figueras M, Moore-Carrasco R, Lopez-Soriano FJ, Fearon KCH, et al. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr. 2007;26:614–8.PubMed

104.

Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer. 2001;84:1135–40.PubMed

105.

Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem. 2006;75:19–37.PubMed

106.

Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88:1478–85.PubMed

107.

Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283:E154–64.PubMed

108.

Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol. 2001;56:M266–72.

109.

Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647–53.PubMed

110.

Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661–7.PubMed

111.

Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc. 2000;48:550–3.PubMed

112.

Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl. 1999;22:300–6.PubMed

113.

Clague JE, Wu FC, Horan MA. Difficulties in measuring the effects of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999;22:261–5.PubMed

114.

Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab. 2002;87:5649–57.PubMed

115.

Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol Endocrinol Metab. 1995;269:E820–6.

116.

Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E601–7.PubMed

117.

Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 1982;42:2495–8.PubMed

118.

Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol. 2000;161:73–88.PubMed

119.

Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv. 2001;56:361–76.PubMed

120.

Hein L, Barsh GS, Bratt RE, Dzau VJ, Koblika BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2-receptor gene in mice. Nature. 1995;377:744–7.PubMed

121.

Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106:2583–91.PubMed

122.

Jones TE, Stephenson KW, King JG, Knight KR, Marshall TL, Scott WB. Sarcopenia—mechanisms and treatments. J Geriatr Phys Ther. 2009;32:39–45.PubMed

123.

Mock V, Dow KH, Meares CJ, Grimm PM, Dienemann JA, Haisfield-Wolfe ME, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum. 1997;24:991–1000.PubMed

124.

Dimeo FC, Stieglitz RD, Novello-Fischer U, Fetscher S, Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999;85:2273–7.PubMed

125.

Nieman DC, Cook VD, Henson DA, Suttles J, Rejeski WJ, Ribisl PM, et al. Moderate exercise training and natural killer cell cytotoxic activity in breast cancer patients. Int J Sports Med. 1995;16:334–7.PubMed

126.

Deuster PA, Morrison SD, Ahrens RA. Endurance exercise modifies cachexia and tumor growth in rats. Med Sci Sports Exerc. 1985;17:385–92.PubMed

127.

Daneryd P, Hafstroem L, Svanberg E, Karlberg I. Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur J Cancer. 1995;31A:97–103.PubMed

128.

Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25:4396–404.PubMed

129.

Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomark Prev. 2005;14:1672–80.

130.

Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653–9.PubMed

131.

Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38:2045–52.PubMed

132.

Mueller M, Breil FA, Vogt M, Steiner R, Lippuner K, Popp A, et al. Different response to eccentric and concentric training in older men and women. Eur J Appl Physiol. 2009;107:145–52.PubMed

133.

Van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GL, Dekhuijzen PN. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc. 2006;38:1543–52.PubMed

134.

Galvao DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, et al. Endocrine and immune response to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis. 2008;11:160–5.PubMed

135.

Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL- 6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75:40–7.PubMed

136.

Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha; production in humans. FASEB J. 2003;17:884–6.PubMed

137.

Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, et al. Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal muscle. Circulation. 2005;111:1763–70.PubMed

138.

Fujita S, Abe T, Drummond MJ, Cadenas JG, Dreyer HC, Sato Y, et al. Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis. J Appl Physiol. 2007;103:903–10.PubMed

139.

Baar K, Esser K. Phosphorylation of p70S6k correlates with increased skeletal muscle mass following resistance exercise. Am J Physiol Cell Physiol. 1999;276:C120–7.

140.

Wang XH, Du J, Klein JD, Bailey JL, Mitch WE. Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int. 2009;76:751–9.PubMed

141.

Lenk K, Schur R, Linke A, Erbs S, Matsumoto Y, Adams V, et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail. 2009;11:342–8.PubMed

142.

Vogiatzis I, Simoes DCM, Stratakos G, Kourepini E, Terzis G, Manta P, Athanasopoulos D, Roussos C, Wagner PD, Zakynthinos S. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J. 2010;36:301–10.

143.

von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010. doi:10.1007/s13539-010-0003-5

Title: Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training
Authors: Karsten Lenk
Gerhard Schuler
Volker Adams
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Journal of Cachexia, Sarcopenia and Muscle / Issue 1/2010
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI: https://doi.org/10.1007/s13539-010-0007-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study

Cachexia as a major underestimated and unmet medical need: facts and numbers

Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle

Abstracts of the 5th Cachexia Conference, Barcelona, Spain, December 5–8, 2009

Systemic zinc redistribution and dyshomeostasis in cancer cachexia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page